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ABSTRACT 21 
Aspects of intrinsic antiviral immunity are mediated by promyelocytic leukaemia (PML)-nuclear 22 
body (PML-NB) constituent proteins.  During herpesvirus infection, these antiviral proteins are 23 
independently recruited to nuclear domains that contain infecting viral genomes to cooperatively 24 
promote viral genome silencing.  Central to the execution of this particular antiviral response is 25 
the small ubiquitin-like modifier (SUMO) signalling pathway.  However, the participating 26 
SUMOylation enzymes are not fully characterized.  We identify the SUMO ligase Protein 27 
Inhibitor of Activated STAT1 (PIAS1) as a constituent PML-NB protein.  We show that PIAS1 28 
localizes at PML-NBs in a SUMO interaction motif (SIM)-dependent manner that requires 29 
SUMOylated or SUMOylation competent PML.  Following infection with herpes simplex virus 30 
1 (HSV-1), PIAS1 is recruited to nuclear sites associated with viral genome entry in a SIM-31 
dependent manner, consistent with the SIM-dependent recruitment mechanisms of other well 32 
characterized PML-NB proteins.  In contrast to Daxx and Sp100, however, the recruitment of 33 
PIAS1 is enhanced by PML.  PIAS1 promotes the stable accumulation of SUMO1 at nuclear 34 
sites associated with HSV-1 genome entry, whereas the accumulation of other evaluated PML-35 
NB proteins occurs independently of PIAS1.  We show that PIAS1 cooperatively contributes to 36 
HSV-1 restriction through mechanisms that are additive to those of PML and cooperative with 37 
those of PIAS4.  The antiviral mechanisms of PIAS1 are counteracted by ICP0, the HSV-1 38 
SUMO-targeted ubiquitin ligase, which disrupts the recruitment of PIAS1 to nuclear domains 39 
that contain infecting HSV-1 genomes through mechanisms that do not directly result in PIAS1 40 
degradation. 41 
Importance.  Adaptive, innate, and intrinsic immunity cooperatively and efficiently restrict the 42 
propagation of viral pathogens.  Intrinsic immunity mediated by constitutively expressed cellular 43 
proteins represents the first line of intracellular defence against infection.  PML-NB constituent 44 
proteins mediate aspects of intrinsic immunity to restrict herpes simplex virus 1 (HSV-1), as well 45 
as other viruses.  These proteins repress viral replication through mechanisms that rely on 46 
SUMO signalling.  However, the participating SUMOylation enzymes are not known.  We 47 
identify the SUMO ligase PIAS1 as a constituent PML-NB antiviral protein.  This finding 48 
distinguishes a SUMO ligase that may mediate signalling events important in PML-NB-mediated 49 
intrinsic immunity.  Moreover, this research complements the recent identification of PIAS4 as 50 
an intrinsic antiviral factor, supporting a role for PIAS proteins as both positive and negative 51 
regulators of host immunity to virus infection. 52 
 53 
 54 
INTRODUCTION 55 
Upon infection the host mounts a coordinated immune response that restricts the replication and 56 
pathogenesis of invading viral pathogens through the combined activities of intrinsic, innate, and 57 
adaptive immunity.  A key distinguishing feature of intrinsic immunity is that it is mediated by 58 
constitutively expressed cellular restriction factors that act to limit the replication and spread of 59 
many viral pathogens [reviewed in (1-3)].  However, the mechanisms that regulate this aspect of 60 
host immunity remain to be fully elucidated.  61 
Crucial to the intrinsic antiviral immune response during herpesvirus infection is the 62 
antiviral activity conferred by core constituent proteins associated with Promyelocytic leukaemia 63 
(PML) nuclear bodies (PML-NBs; also known as Nuclear Domain 10 [ND10]).  Known 64 
restriction factors include PML (TRIpartite Motif 19; TRIM19), Sp100, Daxx, and ATRX, which 65 
influence the intracellular restriction of a diverse range of viruses (4).  PML, the major 66 
scaffolding protein of PML-NBs, is essential for PML-NB formation and coordinates a complex 67 
network of protein interactions dependent on sequences spanning its RBCC (RING, B-box, 68 
Coiled-Coil) tripartite motif (5).  PML-NB formation is also heavily influenced by the post-69 
translational modification of PML by Small Ubiquitin-like Modifier (SUMO) proteins (6-10), 70 
which promote non-covalent protein-protein interactions mediated by SUMO Interaction Motifs 71 
(SIMs) within individual PML-NB component proteins.  Correspondingly, mutation of the 72 
RBCC motif, SUMO modification, or SIM consensus sequences within PML disrupts PML 73 
SUMO modification and the integrity of PML-NBs (9, 10). 74 
SUMO modification regulates many cellular processes, including transcription, stress 75 
response, the cell cycle, and various aspects of host immunity to virus infection [reviewed in (2, 76 
11)].  There are 3 major isoforms of SUMO (SUMO1-3) that are conjugated within mammalian 77 
cells.  SUMO2 and SUMO3 share 97% amino acid identity (henceforth referred to as SUMO2/3) 78 
and can form poly-SUMO chains.  SUMO1 shares ~50% amino acid identity with SUMO2, and 79 
is primarily associated with single SUMO modification or poly-SUMO chain termination events 80 
(12).  Covalent attachment of SUMO to target substrates occurs in a sequential cascade 81 
analogous to that of ubiquitination, requiring E1 activating (SAE1/SAE2 heterodimer), E2 82 
conjugating (Ubc9, also known as UBE2I), and E3 SUMO ligases [reviewed in (13-16)].  Whilst 83 
many SUMO modified substrates are directly conjugated by Ubc9, SUMO ligases enable the 84 
selective modification of substrates in response to a wide range of stimuli, influencing aspects 85 
relating to protein-protein interaction, stability, and sub-cellular localization.  Viruses have 86 
therefore evolved strategies to exploit or inactivate the SUMO pathway during infection in order 87 
to promote their replication [reviewed in (2, 17, 18)].         88 
During herpes simplex virus-1 (HSV-1) infection, SUMO modification plays a key role 89 
in the regulation of PML-NB mediated intrinsic antiviral immunity following viral genome entry 90 
into the nucleus.  SUMO modification, SUMO-SIM interactions, and a functionally active 91 
SUMO pathway all contribute to the recruitment of PML-NB associated restriction factors to 92 
nuclear domains that contain infecting viral genomes (10, 19-21).  Importantly, the recruitment 93 
of Sp100 and Daxx, as well as other SUMO2/3 conjugated proteins, to these domains occurs 94 
independently of PML (21, 22).  The stable recruitment of constituent PML-NB antiviral factors 95 
correlates well with a cooperative restriction in viral gene expression (23, 24), a process that can 96 
limit the onset of productive infection and lead to the establishment of viral quiescence. 97 
HSV-1 counteracts this aspect of host immunity through the expression of ICP0, a viral 98 
E3 ubiquitin ligase with SUMO-Targeted Ubiquitin Ligase (STUbL) properties.  ICP0 induces 99 
the proteasome-dependent degradation or dispersal of PML-NB associated restrictions factors 100 
away from sites that contain infecting viral genomes [reviewed in (2, 25)], as well as broadly 101 
inducing the degradation of many other SUMO conjugated proteins (21, 26).  ICP0 therefore 102 
inhibits the cellular restriction of viral gene expression and creates a favourable environment for 103 
the efficient onset of productive infection.  Accordingly, ICP0-null mutant HSV-1, or HSV-1 104 
mutants that express catalytically inactive ICP0, are more likely to enter into a non-productive 105 
quiescent infection at low multiplicities of infection (27-29).  Importantly, the host-cell 106 
restriction of these viruses can be alleviated through the depletion of PML-NB associated 107 
restriction factors (22-24), inactivation of the SUMO pathway through the depletion of Ubc9 108 
(21) or PIAS4 (30), or saturated upon increased multiplicity of infection (25).  Taken together, 109 
these data highlight a key role for the SUMO pathway in coordinating PML-NB mediated 110 
intrinsic antiviral immunity to HSV-1 infection.  However, the SUMOylation enzymes that 111 
mediate this aspect of host immunity remain to be fully defined. 112 
We recently reported that the SUMO ligase Protein Inhibitor of Activated STAT 4 113 
(PIAS4) contributes to the regulation of intrinsic antiviral immunity to HSV-1 infection in a 114 
manner that is cooperative but independent of PML (30).  Our identification of PIAS4 as an 115 
intrinsic antiviral factor highlights a novel role for this family of proteins that have been 116 
historically characterized as negative regulators of innate immunity [reviewed in (15, 16)].  As 117 
PIAS proteins are known to regulate innate immunity through complementary but distinct 118 
mechanisms, it is plausible that several PIAS proteins may also influence intrinsic antiviral 119 
immunity to virus infection in a PML-NB dependent manner. Consistently, PIAS1 and PIAS2α 120 
have been reported to localize to PML-NBs and to regulate PML SUMO modification (31).  We 121 
therefore investigated the potential roles of other PIAS family members in PML-NB mediated 122 
intrinsic antiviral immunity.   123 
We report that PIAS1 is the only family member to constitutively reside within PML-124 
NBs in uninfected human foreskin fibroblast cells in a PIAS1-SIM and PML SUMOylation-125 
dependent manner.  During infection, PIAS1 was recruited to sites adjacent to HSV-1 genomes, 126 
also in a PIAS1 SIM-dependent manner, where it colocalized with PML-NB constituent proteins 127 
and other SUMO conjugated proteins.  In contrast to Daxx and Sp100 (22), the efficient 128 
recruitment of PIAS1 to these viral induced foci was enhanced by PML.  To our knowledge this 129 
represents the first example of a PML-NB constituent protein that is recruited in a largely PML 130 
dependent manner.  The stable recruitment of PIAS1 to these foci was disrupted by ICP0 without 131 
inducing its proteasomal degradation, similar to ICP0 antagonism of Daxx (32).  Depletion of 132 
PIAS1, either alone or in combination with PML or PIAS4, increased the replication efficiency 133 
of ICP0-null mutant HSV-1 but had no effect on the replication of a wild-type HSV-1.  Taken 134 
together, our data demonstrate that PIAS1 and PIAS4 independently contribute towards the 135 
intrinsic antiviral immune response to HSV-1 infection as part of a coordinated host response to 136 
infection that is ultimately counteracted by the E3 ubiquitin ligase activity of ICP0. 137 
 138 
 139 
MATERIALS AND METHODS 140 
Cells, Drugs, and Viruses.  HFt cells are immortalized human foreskin fibroblasts (HFs) 141 
(Department of Urology, University of Erlangen (22)) stably transduced with a vector that 142 
expresses the catalytic subunit of human telomerase, as described (33).  HFt, HFs, and Retinal 143 
Pigmented Epithelial (RPE-1; ATCC, CRL-4000) cells were maintained in Dulbecco’s Modified 144 
Eagle Medium (DMEM; Life Technologies, 41966).  Human Embryonic Lung (HEL 299; 145 
ECACC, 87042207) fibroblast cells were maintained in Minimum Essential Medium Eagle 146 
(MEM; Sigma-Aldrich M5650) supplemented with 2 mM L-Glutamine (Life Technologies, 147 
25030-024) and 1 mM Sodium Pyruvate (Life Technologies, 11360-039).  HepaRG cells (34) 148 
were maintained in William's medium E (Life Technologies, 22551-022) supplemented with 2 149 
mM L-Glutamine, 5 μg/ml insulin (Sigma-Aldrich, I2643), and 0.5 μM hydrocortisone (Sigma-150 
Aldrich, H4881).  Medium for all cell lines was supplemented with 10% foetal bovine serum 151 
(FBS; Life Technologies, 10270), 100 units/ml penicillin, and 100 μg/ml streptomycin (Life 152 
Technologies, 15140-122).  Cells were maintained at 37oC in 5% CO2.  HFt cells have an 153 
equivalent level of restriction of ICP0-null mutant HSV-1 replication as do HFs cells (data not 154 
shown). 155 
MG132 (Calbiochem, 474790) prepared at 10 mM in DMSO (Sigma-Aldrich, D2650) 156 
was used at 10 μM.  Doxycycline (DOX; Sigma-Aldrich, D9891) prepared at 1 mg/ml in Milli-Q 157 
H2O was used at 0.1 µg/ml.  For transgenic cells, Hygromycin (Invitrogen, 10687-010), 158 
Puromycin (Puro; Sigma-Aldrich, P8833), or Neomycin (Neo; Sigma-Aldrich, A1720) were 159 
used at 50 µg/ml, 1 µg/ml, or 1 mg/ml respectively, during selection, or 5 µg/ml, 0.5 µg/ml, 0.5 160 
mg/ml respectively, for maintenance. 161 
Wild-type HSV-1 strain 17syn+, ICP0-null mutant HSV-1 strain dl1403 (27), or their 162 
respective variants that express eYFP.ICP4 (35) were used.  Viruses were grown and titrated as 163 
described (29).  When used, MG132 was added 1 h after overlay of the inoculum.  For infection 164 
of inducible transgenic cell lines, eYFP or eYFP fusion protein expression was induced with 165 
DOX for 4 h prior to infection in the absence of DOX.  Infected cell monolayers were then 166 
overlaid with the appropriate media supplemented with DOX for the duration of the infection. 167 
 168 
Plasmids and Lentiviral Transduction.  An eYFP encoding sequence was PCR amplified and 169 
subcloned into the TOPO vector (Invitrogen) prior to insertion of the PIAS1 cDNA (Source 170 
Bioscience) between the EcoRI and KpnI restriction sites.  The resultant eYFP.PIAS1 expression 171 
cassette was subcloned into the lentiviral vector pLKO.dCMV.TetO/R (36) using the NheI and 172 
SalI restriction sites.  The primers used for PCR mutagenesis of PIAS1 and the resultant 173 
mutations are described in Table 1.  All clones were confirmed by sequencing.  Lentivirus 174 
vectors that express short hairpin (sh) RNAs against a non-targeted control sequence (shCtrl), 175 
PML (shPML) (22), PIAS4 (shPIAS4) (30), or PIAS1 (shPIAS1; based on: 5' 176 
TTGTAAGTCGTAAGGCATGGG 3') were obtained from the MISSION shRNA lentivirus 177 
vector collection (Sigma-Aldrich).  Lentiviral supernatant stocks were produced and HFt cells 178 
were transduced as described (22).  Transgenic cells were pooled for experimentation.  179 
Transgenic HFt cells that expressed shRNA against PML were reconstituted with PML isoform I 180 
(PML.I) or a SUMOylation deficient PML isoform I (PML.I.4KR; substitution mutations at 181 
lysine residues 65, 160, 490 and 616) as described (10).  182 
 183 
Antibodies.  Primary rabbit: anti-actin (Sigma-Aldrich, A5060), anti-Daxx (Upstate, 07-471), 184 
anti-PIAS1 (LsBio, LS-B9173), anti-PIAS2 (LsBio, LS-C108717), anti-PIAS3 (LsBio, LS-185 
C98795), anti-PIAS4 (LsBio, LS-C108719), anti-PML (Bethyl Laboratories, A301-167A), and 186 
anti-Sp100 (SpGH (37)).  Primary mouse: anti-ICP0 (11060, (38)), anti-ICP4 (58S, (39)), anti-187 
Daxx (AbD Serotec, MCA2143), anti-SUMO1 (Invitrogen, 33-2400), anti-SUMO2/3 (Abcam, 188 
ab81371), anti-UL42 (Z1F11 (40)), and anti-VP5 (DM165, (41)).  Primary sheep: anti-SUMO1 189 
(Enzo Life Sciences, BML-PW0505) and anti-SUMO2/3 (Enzo Life Sciences, BML-PW0510).  190 
Secondary antibodies: peroxidase conjugated anti-mouse IgG (Sigma-Aldrich, A4416), DyLight 191 
-680 or -800 conjugated goat anti-rabbit or -mouse IgG (Thermo), and Alexa-Fluor -488, -555, 192 
or -633 conjugated donkey anti-rabbit, -sheep or -mouse IgG (Invitrogen). 193 
 194 
Immunofluorescence and Confocal Microscopy.  HFt cells (1x105) seeded on 13-mm glass 195 
coverslips in 24-well plates were incubated at 37°C in 5% CO2 overnight.  For infections, virus 196 
was diluted in serum free DMEM to the multiplicity of infection (MOI) indicated in the 197 
corresponding figure legend.  Inoculum was adsorbed for 1 h at 37°C in 5% CO2 with rocking 198 
and rotating every 10 min, prior to overlay with 37°C cell appropriate media containing 2% 199 
Human Serum (HS; MP Biomedicals, 0929301).  To examine the recruitment of host factors to 200 
nuclear sites associated with HSV-1 genome entry or replication compartments, cells were 201 
typically infected at a low MOI for 16 h in order to visualize the distribution of host factors 202 
within newly infected cells at the periphery of a developing plaque edge (20).  Fixation and 203 
immunostaining were performed at room temperature.  Cells were washed twice in CSK buffer 204 
(10 mM Hepes, 100 mM NaCl, 300 mM Sucrose, 3 mM MgCl2, 5 mM EGTA), fixed and 205 
permeablised in 1.8% formaldehyde (Sigma-Aldrich, F8775) and 0.5% Triton-X100 (Sigma-206 
Aldrich, T-9284) in CSK for 10 min, then washed three times in CSK.  Cells were blocked in 2% 207 
HS in PBS (Sigma-Aldrich, D1408) for 10 min, incubated with primary antibodies diluted in 2% 208 
HS in PBS for 90 min, then washed three times in PBS.  DAPI (Sigma-Aldrich, D9542) and 209 
secondary antibodies diluted 1:1000 in 2% HS in PBS were added to the cells for 60 min, prior 210 
to three washes in PBS and two in Milli-Q H2O.  Coverslips were then mounted on glass slides 211 
with a glycerol-based mounting medium (Citifluor, AF1) and sealed with nail enamel.  Samples 212 
were examined with a Zeiss LSM 710 confocal microscope with 405 nm, 488 nm, 543 nm, and 213 
633 nm laser lines under a Plan-Apochromat oil immersion lens, numerical aperture 1.4.  Zen 214 
2012 software (Zeiss) was used to generate cut mask channels and weighted colocalization 215 
coefficients.  Three dimensional image reconstruction was performed with Imaris (Bitplane) 216 
software.  Images were minimally processed with Adobe Photoshop prior to assembly for 217 
publication with Adobe illustrator.  218 
 219 
Western Blot.  HFt cells (1.5 or 2.0 x 105) seeded in 12 well dishes were incubated overnight at 220 
37°C with 5% CO2, or for at least 4 h prior to further manipulation.  For infection, 10 plaque 221 
forming units (PFU) per cell of wild-type or ICP0-null mutant HSV-1 were diluted in serum free 222 
DMEM.  Inoculum was adsorbed for 1 h at 37°C in 5% CO2 with rocking and rotating every 10 223 
min, 37°C cell appropriate media was added, then cells were incubated at 37°C in 5% CO2 until 224 
harvest.  Cells were washed twice with room temperature PBS and whole cell lysates were 225 
collected in SDS-PAGE loading buffer with 4 M Urea (Sigma-Aldrich, U0631) and 50 mM 226 
Dithiothretol (DTT, Sigma-Aldrich, D0632).  Proteins resolved using standard Tris-glycine or 227 
Tris-tricine SDS-PAGE systems were electrotransferred onto 0.2 μm nitrocellulose membrane 228 
(Amersham, 15249794) at 250 mA for 150 (Tris-tricine) or 180 (Tris-glycine) min in Towbin 229 
buffer (25mM Tris, 192 mM glycine, 20% v/v methanol) at room temperature.  Membranes were 230 
blocked in 5% FBS in PBS overnight at 4°C.  Subsequent steps were performed on a roller 231 
apparatus at room temperature.  Membranes incubated with primary antibody diluted in 5% FBS 232 
in PBS with 0.1% Tween (PBST; Calbiochem, 655204) for 2 h, were washed in PBST three 233 
times for 5 min each, then incubated with secondary antibody diluted 1:10,000 in 5% FBS in 234 
PBST for 1 h.  Following three 5 min washes in PBST, one 5 min wash in PBS, and one rinse in 235 
Milli-Q H2O, membranes were imaged on an Odyssey Infrared Imager (Licor).  The intensity of 236 
protein bands was quantified using Odyssey Image Studio software. 237 
 238 
Plaque Forming Efficiency (PFE).  HFt cells (1 x 105) seeded in 24-well plates were incubated 239 
at 37°C in 5% CO2 overnight.  Wild type or ICP0-null mutant HSV-1 was serially diluted in 240 
serum free DMEM.  Cells inoculated with sequential viral dilutions were rocked and rotated 241 
every 10 min for 1 h, then overlaid with 37°C cell appropriate media supplemented with 2% HS.  242 
Subsequent steps were performed at room temperature.  24 h post infection (hpi), cells were 243 
washed twice in PBS, fixed in 1.8% formaldehyde and 0.1% NP40 (BDH, 56009) in PBS for 10 244 
min, then washed in PBST twice.  Cells were blocked with 5% (w/v) skimmed milk powder 245 
(SMP; Marvel) in PBST for 30 min then incubated with anti-VP5 antibody diluted in 5% SMP in 246 
PBST for 90 min.  Following three washes in PBST for 5 min each, peroxidase conjugated anti-247 
mouse IgG (Sigma-Aldrich, A4416) diluted in 5% SMP in PBST was added for 60 min.  Cells 248 
were washed in PBST three times, then plaques were visualised using True Blue peroxidase 249 
developing solution (Insight, 50-78-02), according to the manufacturer’s instructions. 250 
 251 
Quantitative RT-PCR.  1.5 or 2.0 x 105 HFt cells seeded in 12-well plates were incubated at 252 
37°C in 5% CO2 overnight, or for at least 4 h before further manipulation.  Cells were washed 253 
with PBS and total RNA was isolated using the RNAeasy Plus Kit (Qiagen, 74137) or Trizol 254 
reagent (Invitrogen, 15596) following the manufacturer’s instructions.  cDNA was synthesised 255 
using the TaqMan Reverse Transcription Reagents kit (Life Technologies, N8080234) with oligo 256 
(dT) primers.  Samples were analysed in triplicate using TaqMan Fast Universal PCR Master 257 
Mix (Life Technologies, 4352042) with the following TaqMan gene specific primer-258 
(FAM/MGB) probe mixes (Life Technologies): PML (Hs00231241_m1), PIAS1 259 
(Hs00184008_m1), 18S (accession number X03205.1), or GAPDH (4333764F). 260 
 261 
 262 
RESULTS 263 
PIAS1 is a constituent PML-NB protein. 264 
Although PML-NB-mediated restriction of viral replication is executed in part through SUMO-265 
dependent processes (10, 21), the specific contributions of SUMOylation enzymes to this aspect 266 
of intrinsic immunity are not fully known.  Using HFt human fibroblasts, which provide an 267 
amenable system to study PML-NB-mediated intrinsic immunity, we recently reported that the 268 
SUMO E3 ligase PIAS4 is an intrinsic antiviral factor.  Even though PIAS4 is not a major PML-269 
NB constituent protein in HFt cells (30), it is possible that several PIAS proteins confer intrinsic 270 
antiviral activity and that some of which could regulate PML-NB-mediated viral restriction.  To 271 
initiate investigation into the potential roles of PIAS proteins in PML-NB-mediated intrinsic 272 
immunity, whether any PIAS protein is a prominent constituent of PML-NBs in HFt cells was 273 
evaluated.  PIAS proteins were predominantly nuclear in HFt cells and largely associated with 274 
matrix associated regions (MARs; Fig. 1A) (30).  PIAS1 was the only family member that 275 
accumulated in punctate structures, which were identified to be PML-NBs by colocalization with 276 
PML (Fig. 1A) (30, 31).  This localization of PIAS1 at PML-NBs was not unique to HFt cells 277 
and was evident in several other evaluated cell lines, including non-immortalized fibroblasts 278 
(HFs, HEL), hepatocytes (HepaRG), and epithelial cells (RPE) (Fig. 1C).  The colocalization of 279 
PIAS1 with PML within HFt cells was nearly as prominent as that of Daxx, a major constituent 280 
protein of PML-NBs (Fig. 1) (42).  The average weighted coefficient for colocalization of Daxx 281 
and PML was 0.89, whereas that of PIAS1 and PML was 0.65 (Fig. 1B).  In contrast, PIAS2, 282 
PIAS3, and PIAS4 had minimal, if any, colocalization with PML (Fig. 1).  These data identify 283 
PIAS1 as the only PIAS protein that substantially localizes to PML-NBs in HFt cells.  284 
 285 
The localization of PIAS1 at PML-NBs is SIM-dependent and requires SUMOylated PML. 286 
SUMO-SIM interactions are vital for the localization of many constituent proteins at PML-NBs 287 
in uninfected cells (7, 8, 43).  The role of SUMO-SIM interactions to mediate the steady state 288 
association of PIAS1 with PML-NBs was therefore evaluated.  HFt cells were stably transduced 289 
with lentiviral vectors that could be induced to express eYFP or eYFP fused to wild-type PIAS1 290 
or PIAS1 with point mutations in its SIM domain (Fig. 2A; Table 1).  EYFP did not localize at 291 
PML-NBs (Fig 2B and D), nor did fusion to eYFP adversely affect PIAS1 localization at PML-292 
NBs (Fig. 2C and E).  Following short periods of induction PIAS1 colocalized with PML-NBs, 293 
however, the sustained ectopic expression of PIAS1 (16 h) disrupted them (Fig. 2C) (30, 31).  To 294 
avoid such adverse effects, catalytically inactive PIAS1 (eYFP.P1.C351A; Table 1) was 295 
subsequently used (44).  Inactivation of the PIAS1 SUMO ligase activity did not abrogate PIAS1 296 
localization at PML-NBs, nor did expression of this mutant disrupt PML-NBs (Fig. 2F, middle 297 
panel).  Additional mutation of the SIM abrogated the localization of PIAS1 at PML-NBs (Fig. 298 
2F, bottom panel), demonstrating that PIAS1 localizes to PML-NBs in a SIM-dependent manner 299 
that is largely independent of its SUMO-ligase activity.   300 
 The localization of PIAS1 at PML-NBs was evaluated in PML-depleted cells stably 301 
reconstituted with PML isoform I (eYFP.PML.I) or PML.I with substitution mutations in the 302 
four major SUMOylation acceptor sites (eYFP.PML.I.4KR) to test the potential dependency of 303 
PIAS1 localization at PML-NBs on PML SUMOylation (5, 10).  PML depletion was achieved 304 
through the stable transduction of vectors that express PML specific short hairpin (sh) RNA (9, 305 
22).  The depletion of PML did not obviously affect PIAS1 expression (Fig. 3A).  In the absence 306 
of PML, and consequently PML-NBs (7, 8), PIAS1 primarily localized to MARs (Fig. 3B).  307 
Reconstitution of PML depleted cells with eYFP did not stimulate the formation of PML-NBs or 308 
otherwise alter PIAS1 sub-nuclear localization (data not shown), whereas reconstitution with 309 
eYFP.PML.I was sufficient to nucleate PML-NB formation and PIAS1 associated with these 310 
structures (Fig. 3C).  SUMO-modification of PML is essential for the proper assembly of PML-311 
NBs (7, 8, 43), therefore, reconstitution with SUMOylation deficient PML.I resulted in the 312 
formation of aberrant aggregates (Fig. 3D) (8, 10).  Some PML-NB constituent proteins, such as 313 
Daxx and SUMO1, associated with these aggregates while others, such as Sp100 and SUMO2/3, 314 
largely did not (Fig. 3D).  The localization of Daxx at PML-NBs is largely mediated through 315 
SIM-dependent association with SUMO1, thus SUMO1 interaction with the PML.I.4KR SIM, or 316 
the localization of an alternative SUMO1-modified protein at the PML.I.4KR aggregates, likely 317 
mediated this association of Daxx (7, 43).  In contrast, PIAS1 did not localize at the aggregates 318 
of SUMOylation deficient PML.  This data demonstrates that SUMO-modified, or SUMOylation 319 
competent, PML is required for the stable association of PIAS1 at PML-NBs and that Daxx or 320 
SUMO1 are not sufficient to mediate this association in the absence of SUMOylation competent 321 
PML.   322 
 323 
The localization of PIAS1 at nuclear domains that contain infecting HSV-1 genomes is 324 
disrupted by ICP0. 325 
ICP0 counteracts PML-NB-mediated intrinsic immunity by targeting specific antiviral proteins 326 
for proteasome-dependent degradation or dispersal away from infecting viral genome foci 327 
[reviewed in (25)].  Therefore, prior to investigation into the potential roles of PIAS1 in intrinsic 328 
immunity, PIAS1 protein levels were evaluated during HSV-1 infection to ascertain whether it is 329 
a substrate for ICP0-mediated degradation.  HFt cells infected with wild-type HSV-1 had a 330 
continued decrease in PIAS1 protein levels as infection progressed, down to 56 ± 9% of the 331 
levels in mock-infected cells by 9 hours post infection (hpi; Fig. 4A and B; P ≤ 0.01).  In 332 
contrast, PML, which is a direct target of ICP0, had a substantial loss (typically 50-70%) in 333 
protein levels as early as 3 hpi (Fig. 4A).  In the absence of ICP0, a significant loss in PIAS1 334 
protein levels was not observed (Fig. 4A and B).  Given the kinetics of PIAS1 degradation and 335 
the lack of direct interaction with ICP0 (45), PIAS1 is not likely a substrate for ICP0-targetted 336 
proteasomal degradation. 337 
The relocalization of PML-NB constituent proteins from punctate PML-NBs throughout 338 
the nucleus to a nuclear edge associated with HSV-1 genome entry is characteristic of the PML-339 
NB-mediated intrinsic immune response (for example see Fig. 4C PML, Daxx: ΔICP0) (10, 20).  340 
During ICP0-null mutant HSV-1 infection, PIAS1 also relocalized to the nuclear edge that 341 
contained infecting viral genomes, which was identified by the localization of PML or Daxx, and 342 
the HSV-1 DNA-binding protein ICP4 (Fig. 4C; ΔICP0).  Reconstruction of a z-stack series of 343 
confocal microscopy images demonstrated that PIAS1 and PML colocalized at the nuclear edge 344 
associated with viral genome entry (Pearson coefficient 0.558), although foci that predominantly 345 
contained only PML or PIAS1 were also evident (Fig. 4D).  The relocalization of PIAS1 to 346 
nuclear domains that contained infecting HSV-1 genomes was disrupted during wild-type HSV-1 347 
infection (Fig. 4C; HSV-1).  Under these infection conditions PIAS1 had a nuclear diffuse 348 
distribution similar to that of Daxx (Fig. 4C; HSV-1).   349 
These data demonstrate that PIAS1 is recruited to nuclear domains that contain infecting 350 
HSV-1 genomes in a manner that is disrupted by ICP0 through mechanisms that do not directly 351 
target PIAS1 for degradation. 352 
 353 
PML enhances PIAS1 SIM-dependent localization at nuclear domains that contain 354 
infecting HSV-1 genomes. 355 
Constituent PML-NB antiviral proteins are individually recruited to nuclear domains that contain 356 
infecting HSV-1 genomes through SUMO-dependent mechanisms that are independent of PML 357 
(10, 20, 22).  To initiate characterization of the recruitment mechanisms of PIAS1, its 358 
recruitment phenotype was evaluated in PML depleted cells.  Robust depletion of PML was 359 
achieved through the stable transduction of plasmids that express PML specific shRNA (Figs. 360 
3A, B and 5A) (22).  As expected, Daxx was recruited to the nuclear edge associated with ICP0-361 
null mutant HSV-1 genome entry independently of PML (Fig. 5A) (10, 22).  In contrast, PIAS1 362 
recruitment was significantly diminished in the absence of PML (Fig. 5A), suggesting that this 363 
process is largely PML-dependent.  PIAS1 was still stably recruited to nuclear domains that 364 
contained infecting viral genomes in cells that expressed non-targeted control shRNAs, 365 
confirming that the lack of recruitment was due to PML depletion and not transduction or the 366 
selection of transgenic cells (Fig. 5A).  These data demonstrate that PML promotes the stable 367 
accumulation of PIAS1 in nuclear domains that contain infecting HSV-1 genomes.  368 
 Thus far, PIAS1 represents the first PML-NB constituent protein that is recruited to 369 
domains that contain infecting HSV-1 genomes through mechanisms that are enhanced by PML.  370 
As the association of PIAS1 with PML-NBs is SIM-dependent, the role of the SIM in the 371 
recruitment mechanism of PIAS1 was evaluated.  Mutation of the SIM substantially reduced 372 
PIAS1 accumulation at the nuclear edge that contained infecting ICP0-null mutant HSV-1 373 
genomes (Fig. 5B, ΔICP0 bottom panel).  The reduced accumulation of mutant PIAS1 was not 374 
due to the inactivation of its catalytic activity as the inactive PIAS1 mutant with a functional 375 
SIM still stably accumulated in nuclear domains that contained infecting viral genomes (Fig. 5B, 376 
ΔICP0 middle panel).  As the expression levels of the mutant PIAS1 proteins were similar (Fig. 377 
5C), the reduced accumulation of the SIM mutant was not due to overexpression saturating 378 
potential binding sites within the nuclear domains that contained infecting viral genomes.  As 379 
expected, ICP0-mediated degradation of PML abrogated the recruitment of PIAS1 to the nuclear 380 
periphery associated with infecting HSV-1 genomes regardless of any mutations to PIAS1 (Fig. 381 
5B, HSV-1).  382 
 These data demonstrate that PIAS1 is recruited to nuclear domains that contain infecting 383 
HSV-1 genomes through SIM-dependent mechanisms that are enhanced by PML.  Furthermore, 384 
the stable localization of PIAS1 at the nuclear edge associated with HSV-1 genome entry is 385 
likely independent of PIAS1 catalytic activity. 386 
 387 
PIAS1 is not essential for PML SUMO modification or the formation of PML-NBs. 388 
The potential functional significance of PIAS1 to regulate the association of select PML-NB 389 
constituent proteins at PML-NBs or their stable accumulation in nuclear domains that contain 390 
infecting HSV-1 genomes was tested in PIAS1 depleted cells.  Transgenic HFt cells that 391 
expressed PIAS1 specific shRNA had a marked reduction in PIAS1 expression relative to cells 392 
that expressed non-targeted control shRNA (Fig. 6A).  After limited passaging, however, PIAS1 393 
protein expression recovered to levels similar to those in transgenic cells that expressed control 394 
shRNA (data not shown).  Experiments were therefore conducted over multiple rounds of 395 
independent transduction with minimal passaging of the isolated transgenic cells.  The depletion 396 
of PIAS1 did not noticeably alter PML expression or SUMO-modification (Fig. 6A) (31).  397 
Furthermore, the association of the major constituent PML-NB proteins Daxx, SUMO1, or 398 
SUMO2/3 at PML-NBs, or the relative size and number of PML-NBs per nuclei, were not 399 
noticeably altered following PIAS1 depletion (Fig. 6B and C).   400 
 PML, Daxx, or SUMO2/3 still localized to sites associated with infecting ICP0-null 401 
mutant HSV-1 genomes in PIAS1 depleted cells (Fig. 6D), demonstrating that PIAS1 is not 402 
necessary for their stable accumulation in these domains.  In contrast, the accumulation of 403 
SUMO1 at the nuclear edge associated with viral genome entry was notably reduced in PIAS1 404 
depleted cells (Fig. 6D), highlighting a role for PIAS1 in the stable accumulation of SUMO1 at 405 
these sites.  As expected, ICP0 efficiently disrupted the localization of constituent PML-NB 406 
antiviral proteins at nuclear domains that contained infecting HSV-1 genomes regardless of the 407 
presence or absence of PIAS1 (data not shown).   408 
These data demonstrate that PIAS1 is not essential for PML SUMOylation or the proper 409 
formation of PML-NBs.  During ICP0-null mutant HSV-1 infection, PIAS1 is differentially 410 
required for the stable localization of constituent PML-NB proteins at nuclear domains that 411 
contain infecting viral genomes.  The stable accumulation of SUMO1 at such domains is 412 
enhanced by PIAS1, whereas PML, SUMO2/3, or Daxx effectively re-localize to such domains 413 
independently of PIAS1.  414 
 415 
PIAS1 contributes to the cellular restriction of ICP0-null mutant HSV-1. 416 
To test the functional significance of PIAS1 during infection, the replication of wild-type or 417 
ICP0-null mutant HSV-1 was evaluated in cells depleted of PIAS1, or PML as a positive control 418 
(22).  Transgenic HFt cells that expressed PIAS1 or PML specific shRNA, alone or in 419 
combination, had greater than 80% depletion in the specific target mRNA and a substantial 420 
reduction in the corresponding protein levels relative to cells that expressed non-targeted control 421 
shRNA (Fig. 7A and B).  The depletion of PIAS1 did not substantially alter the plaque forming 422 
efficiency (PFE) of wild-type HSV-1, demonstrating that PIAS1 is not essential for HSV-1 423 
replication (Fig. 7C).  In contrast, the PFE of ICP0-null mutant HSV-1 was enhanced 10-fold in 424 
PIAS1 depleted cells, which was comparable to the increase observed following PML depletion 425 
(Fig. 7C).  PIAS1 is thus identified as an intrinsic antiviral factor that contributes to the 426 
intracellular restriction of ICP0-null mutant HSV-1.   427 
As the depletion of PIAS1 or PML resulted in a similar relief of restriction in ICP0-null 428 
mutant HSV-1 replication, and PML facilitates the stable accumulation of PIAS1 in domains that 429 
contain infecting HSV-1 genomes, it is possible that the mechanisms of PIAS1 and PML-430 
mediated viral restriction are sequential.  To test this possibility, HSV-1 replication was 431 
evaluated in cells co-depleted for PML and PIAS1 (Fig. 7A and B).  In the absence of PIAS1 and 432 
PML, the PFE of ICP0-null mutant HSV-1 was twice that in cells depleted of either protein alone 433 
(Fig. 7C).  This data suggests that the antiviral mechanisms of PIAS1 and PML are likely 434 
additive.  Under conditions in which PIAS1 and PML were co-depleted, the replication of wild-435 
type HSV-1 was not substantially affected, confirming that neither protein is essential for viral 436 
replication and that ICP0 is sufficient to counteract their intrinsic antiviral activities (Fig. 7C).  437 
 438 
The intrinsic antiviral mechanisms of PIAS1 and PIAS4 are cooperative. 439 
The identification of PIAS1 as an intrinsic antiviral PML-NB constituent protein complements 440 
the recent identification of PIAS4 as an intrinsic antiviral factor (30).  As PIAS4 localizes to 441 
domains that contain HSV-1 genomes throughout infection (30), whether or not PIAS1 also 442 
accumulates in replication compartments was evaluated.  During ICP0-null mutant HSV-1 443 
infection, PIAS1 localized to replication compartments, although this localization phenotype was 444 
less prominent than that of PIAS4 (Fig. 8A).  Moreover, the localization of PIAS1 in HSV-1 445 
replication compartments was disrupted by ICP0 (Fig. 8B), whereas PIAS4 remained associated 446 
with replication compartments irrespective of ICP0 expression (Fig. 8B) (30).   447 
 To test the functional relationship between the antiviral activities of PIAS1 and PIAS4, 448 
HSV-1 replication was evaluated in cells depleted of both proteins.  Transgenic HFt cells that 449 
expressed PIAS1 or PIAS4 specific shRNA had considerable, although not full, depletion of 450 
either protein (Fig. 8C).  Single or co-depletion of PIAS1 and PIAS4 did not substantially alter 451 
the replication of wild-type HSV-1, confirming that ICP0 is sufficient to counteract their 452 
antiviral activities and that these proteins are not essential for HSV-1 replication (Fig. 8D).  453 
Depletion of either PIAS1 or PIAS4 enhanced the replication of ICP0-null mutant HSV-1 to a 454 
similar degree, while co-depletion of PIAS1 and PIAS4 enhanced it to an even greater degree 455 
than did single depletion alone (Fig. 8D).  PIAS1 and PIAS4 therefore likely mediate the 456 
restriction of ICP0-null mutant HSV-1 through cooperative but independent mechanisms, 457 
suggesting that the complementary functional roles of PIAS proteins in the regulation of innate 458 
immunity are mirrored in their regulation of intrinsic immunity.   459 
   460 
 461 
DISCUSSION 462 
We identify PIAS1 as a PML-NB constituent protein that contributes to the repression of ICP0-463 
null mutant HSV-1 replication mediated by the intrinsic antiviral immune response.  PIAS1 464 
associates with PML-NBs through SIM-dependent mechanisms that require SUMOylation 465 
competent PML and is recruited to nuclear domains that contain infecting HSV-1 genomes 466 
through SIM-dependent mechanisms that are enhanced by PML.  The stable accumulation of 467 
SUMO1 at domains that contain infecting HSV-1 genomes is enhanced by PIAS1, while the 468 
stable localization of other major PML-NB constituent proteins at these domains is largely 469 
independent of PIAS1.  The antiviral mechanisms of PIAS1 are additive to those of PML and 470 
cooperative with those of PIAS4.  However, the antiviral activities of PIAS1 are efficiently 471 
counteracted by ICP0, which abrogates the stable accumulation of PIAS1 in nuclear domains that 472 
contain viral genomes. Similar to Daxx, the antagonism of PIAS1 occurs without directly 473 
targeting it for degradation (32). 474 
 PIAS1 is unique amongst the PIAS family of SUMO ligases in that it is the only member 475 
that substantially associates with PML-NBs in HFt cells (Fig. 1) (30).  This localization of 476 
PIAS1 was not restricted to HFt cells, however, as it also colocalized with PML-NBs in other 477 
restrictive cell types (Fig. 1C).  Given that the PIAS family of proteins have highly conserved 478 
SIMs (80% amino acid identity), the SIM-mediated association of PIAS1 with PML-NBs is 479 
likely contextual rather than due to generic interactions with SUMO moieties.  PML.I.4KR 480 
aggregates contain SUMO1, and to a much lesser degree SUMO2/3 (Fig. 3D).  In this context, 481 
SUMO1 is not sufficient to facilitate the stable localization of PIAS1 at the PML.I.4KR 482 
aggregates.  Even though the SIM (VIDLT) of PIAS1 does not preferentially bind to a particular 483 
SUMO isoform (46, 47), peptides that contain the core SIM sequence (I/V)DLT preferentially 484 
bind to SUMO2/3 (48).  PIAS1 localization at PML-NBs could therefore be largely mediated 485 
through SUMO2/3 interactions.  Alternatively, but not exclusively so, specific SUMOylated 486 
proteins, potentially PML, may regulate PIAS1 localization at PML-NBs.  The association of 487 
Sp100 with PML-NBs is not mediated by the Sp100 SIM (49), which superficially suggests that 488 
Sp100 should localize to the PML.I.4KR aggregates (Fig. 3D).  However, the localization of 489 
Sp100 at PML-NBs is mediated by MORC3 (50-52), which does associate with PML-NBs 490 
through SIM-dependent mechanisms (53).  Sp100 association with PML-NBs is thus indirectly 491 
mediated through the SIM of MORC3.  PIAS1 specific interactions with particular SUMOylated 492 
proteins within PML-NBs may therefore provide the specificity for the stable association of 493 
PIAS1, but not other PIAS family members, at these structures.    494 
 The mechanism whereby PIAS1 is recruited to nuclear domains that contain infecting 495 
HSV-1 genomes is similar to that of other PML-NB constituent proteins in that it is SIM 496 
dependent, but is also unique in that it is enhanced by PML.  In the absence of PML, the 497 
localization of PIAS1 at the nuclear edge associated with viral genome entry is substantially 498 
reduced (Fig. 5A), indicating that PML is required for the efficient or stable accumulation of 499 
PIAS1 at these sites.  However, PIAS1 and PML do not fully colocalize within these nuclear 500 
domains and puncta that primarily contain only PIAS1 or PML are evident (Fig. 4D).  These data 501 
suggest that PIAS1 can stably remain within domains that contain infecting HSV-1 genomes 502 
through interactions that are likely independent of PML, however, such interactions are not 503 
sufficient to mediate its stable re-localization in the absence of PML.  Although the accumulation 504 
of PIAS1 in nuclear domains that contain infecting HSV-1 genomes is largely PML-dependent, 505 
the antiviral effects of PIAS1 are additive to those of PML (Fig. 7C), which demonstrates that 506 
they have separate antiviral mechanisms.  Thus, in the absence of PML, and consequently the 507 
stable accumulation of PIAS1 in nuclear domains that contain infecting viral genomes, PIAS1 508 
retains antiviral activities.  Conversely, the antiviral mechanisms of PML are not exclusively 509 
linked to its capacity to recruit PIAS1 to nuclear domains that contain infecting HSV-1 genomes. 510 
 It has been reported that the accumulation of SUMO1 within nuclear domains that 511 
contain infecting HSV-1 genomes represents SUMOylated PML, as conditions that limit the 512 
recruitment of PML also decrease the accumulation of SUMO1 at the recruitment edge (10, 21, 513 
24).  However, we now show that in the absence of PML, the lack of SUMO1 accumulation at 514 
the recruitment edge is likely a secondary effect of the inefficient recruitment of PIAS1 (Figs. 5A 515 
and 6D).  PIAS1 may promote the accumulation of SUMO1 at the recruitment edge through 516 
direct SUMOylation of target substrates.  However, preferential PIAS1-mediated SUMO1-517 
modification rather than SUMO2/3-modification of target substrates has yet to be demonstrated.  518 
Alternatively, PIAS1 could promote the accumulation of SUMO1 at the recruitment edge 519 
through interactions with specific SUMO1-modified proteins.  It is unlikely, however, that the 520 
efficient accumulation of SUMO1 in nuclear domains that contain infecting HSV-1 genomes 521 
represents the primary mechanism of PIAS1 antiviral activity.  The depletion of PML disrupts 522 
PIAS1, and consequently SUMO1, accumulation in nuclear domains that contain infecting HSV-523 
1 genomes.  The accumulation of SUMO1 at such domains is therefore impaired in the absence 524 
of either PML or PIAS1, whereas the depletion of both proteins impairs the intrinsic immune 525 
response to a greater degree than the depletion of either protein alone (Fig. 7C). 526 
 PIAS1 is the only PIAS protein that substantially associates with PML-NBs in HFt cells 527 
(Fig. 1).  However, PML-NB formation, PML SUMOylation, or the localization of SUMO-1 or -528 
2/3 within PML-NBs is not obviously altered in PIAS1 depleted cells (Fig. 6).  This observation 529 
suggests that PIAS1 is largely not responsible for the SUMOylation events that are crucial for 530 
PML-NB stabilization, constitutive PML SUMOylation, or the localization of SUMO-1 or -2/3 at 531 
PML-NBs.  Alternatively, other PIAS family members (or SUMO E3 ligases) may mediate these 532 
events under conditions of PIAS1 depletion, or it is possible that the PIAS1 at PML-NBs largely 533 
functions to regulate PML turnover (31).  However, this later scenario is unlikely as we did not 534 
observe any significant accumulation of unmodified PML following the depletion of PIAS1 (Fig. 535 
6A).  During ICP0-null mutant HSV-1 infection, the depletion of PIAS1 dramatically reduces 536 
SUMO1 accumulation at the nuclear edge that contains infecting HSV-1 genomes (Fig. 6D), 537 
suggesting that other SUMO E3 ligases do not efficiently mediate this particular PIAS1 function.  538 
PIAS1 and PIAS4 are currently the only PIAS proteins identified to be intrinsic antiviral factors 539 
(this manuscript, (30)).  While both proteins localize to nuclear domains that contain viral DNA 540 
throughout infection, PIAS1 is more prominently recruited to domains that contain infecting 541 
HSV-1 genomes while PIAS4 is more prominently recruited into replication compartments (Fig. 542 
8A and B) (30).  The localization phenotypes of PIAS1 and PIAS4 during HSV-1 infection 543 
suggest that they have shared as well as distinct antiviral activities.  Consistently, the antiviral 544 
mechanisms of PIAS1 and PIAS4 are cooperative (Fig. 8D).  Moreover, PIAS1 and PIAS4 both 545 
complement the antiviral activities of PML (Fig. 7C) (30).  Together, these data indicate that 546 
PIAS proteins likely utilize a multi-faceted yet interconnected approach to modulate intrinsic 547 
immunity to achieve the ultimate objective of viral repression. 548 
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 703 
FIGURE LEGENDS 704 
FIG 1.  PIAS1 is a PML-NB constituent protein.  (A) Confocal microscopy images show the 705 
nuclear localization of PIAS1-4 with respect to PML, the major PML-NB scaffolding protein, in 706 
HFt cells. The localization of Daxx, a major PML-NB constituent protein, with respect to PML is 707 
shown for comparison.  PIAS1-4 (red), Daxx (red), and PML (green) were visualised by indirect 708 
immunofluorescence.  Cut mask (yellow) highlights regions of colocalization; weighted 709 
colocalization coefficients are indicated.  (B) Box and whisker plot shows the distribution of 710 
individual weighted colocalization coefficients of Daxx or PIAS1-4 with PML.  The number of 711 
nuclei evaluated for each pairwise comparison is shown.  Box, upper to lower quartile; diamond, 712 
mean; horizontal line, median; upper whisker, maximum value; lower whisker, minimum value.  713 
(C) Confocal microscopy images show the nuclear localization of PIAS1 and PML in HFs, HEL, 714 
HepaRG, or RPE cells. PIAS1 (red) and PML (green) were visualised by indirect 715 
immunofluorescence. Nuclei were stained with DAPI (blue).   716 
 717 
FIG 2.  Ectopic PIAS1 associates with and disrupts PML-NBs in a SIM- and SUMO ligase- 718 
dependent manner.  (A) Diagram highlights the PIAS family conserved functional domains 719 
(grey) within PIAS1. SAP, SAF-A/B, Acinus and PIAS; PINIT, ‘PINIT’ motif; SP-RING, 720 
Siz/PIAS-RING zinc finger; SIM, SUMO interaction motif; C-Term, variable C-terminal 721 
domain.  (B-C) Confocal microscopy images show the nuclear localization of eYFP (B) or 722 
eYFP-PIAS1 (C) with respect to PML.  EYFP or eYFP-PIAS1 expression was DOX induced 723 
(+Dox), or not (-Dox), for 8 or 16 h.  PML (red) was visualized by indirect immunofluorescence.  724 
(D-E) Emission spectra show the pixel intensity and colocalization between PML and eYFP (D) 725 
or eYFP-PIAS1 (E) in the regions indicated by white bars in (B) or (C), respectively.  (F) 726 
Confocal microscopy images show the nuclear localization of eYFP or catalytically inactive 727 
eYFP-PIAS1, with (eYFP.P1.C351A.mSIM) or without (eYFP.P1.C351A) a mutant SIM, with 728 
respect to PML-NBs.  Expression of eYFP or eYFP-PIAS1 mutant proteins was DOX induced 729 
for 16 h.  PML-NBs were identified by the accumulation of PML.  PIAS1 (pAb; red) and PML 730 
(cyan) were visualized by indirect immunofluorescence.  Nuclei were stained with DAPI (blue). 731 
 732 
FIG 3.  PIAS1 localization at PML-NBs requires SUMO-modified PML.  (A) Western blots 733 
show PML and PIAS1 protein levels in transgenic cells that express PML specific shRNA 734 
(shPML) or a non-targeted control sequence (shCtrl).  Whole cell lysates were resolved by Tris-735 
glycine SDS-PAGE.  Membranes were probed for PML or PIAS1, and actin as a loading control.  736 
Molecular weights (MWs) are indicated (kDa).  (B) Confocal microscopy images show the 737 
nuclear localization of PIAS1 in transgenic HFt cells that express shPML or shCtrl.  PIAS1 (red) 738 
and PML (green) were detected by indirect immunofluorescence.  (C-D) Confocal microscopy 739 
images show PIAS1 localization with respect to PML isoform I in PML depleted transgenic HFt 740 
cells stably reconstituted with PML.I (eYFP.PML.I; C) or SUMOylation deficient PML.I 741 
(eYFP.PML.I.4KR; D).  PIAS1 (red), Daxx (red), Sp100 (red), SUMO1 (red), SUMO2/3 (red), 742 
and PML (cyan) were detected by indirect immunofluorescence.  Nuclei were stained with DAPI 743 
(blue). 744 
 745 
FIG 4.  ICP0 disperses PIAS1 away from domains that contain infecting HSV-1 genomes 746 
without targeting it for proteasomal degradation.  (A) Western blots show PIAS1 protein levels 747 
during wild-type or ICP0-null mutant HSV-1 infection.  HFt cells were infected with 10 PFU of 748 
wild-type (HSV-1) or ICP0-null mutant (ΔICP0) HSV-1 per cell in the presence (+) or absence (-749 
) of the proteasome inhibitor MG132.  Whole cell lysates were harvested at 3, 6, or 9 hours post 750 
infection (hpi) and proteins were resolved by Tris-tricine SDS-PAGE.  Membranes were probed 751 
for PIAS1, PML as an example of an ICP0 substrate, ICP0, ICP4, and UL42 to show the 752 
progression of infection, and actin as a loading control.  MWs are indicated (kDa).  (B) Bar 753 
graph shows the average relative levels of PIAS1 during wild-type or ICP0-null mutant HSV-1 754 
infection.  The intensity of PIAS1 protein bands were quantitated from western blots as in (A), 755 
normalised to their respective loading control, and presented as a ratio to the level in mock-756 
infected cells at 9 hpi (1.0).  Means and Standard Error of the Means (SEM) are shown (n = 7). * 757 
P < 0.05, ** P < 0.01; Student’s two-tailed t-test.  (C) Confocal microscopy images show the 758 
accumulation of PIAS1, or lack of it, at the nuclear edge associated with HSV-1 genome entry in 759 
cells within the periphery of a developing plaque (20).  HFt cells were infected with 2 or 0.002 760 
PFU per cell of ICP0-null mutant or wild type HSV-1, respectively, for 16 h.  PIAS1 (red), PML 761 
(cyan), and Daxx (cyan) were detected by indirect immunofluorescence.  The nuclear edge 762 
associated with HSV-1 genome entry was identified by eYFP.ICP4 localization.  Nuclei were 763 
stained with DAPI (blue).  (D) Three-dimensional reconstruction of z-stack series of confocal 764 
microscopy images shows the accumulation of PIAS1 and PML at the nuclear edge associated 765 
with HSV-1 genome entry.  Regions of PML and PIAS1 colocalization (yellow) are highlighted; 766 
Pearson coefficient is indicated. 767 
 768 
FIG 5.  The SIM-dependent localization of PIAS1 at domains that contain infecting HSV-1 769 
genomes is enhanced by PML.  (A) Confocal microscopy images show PIAS1 localization, or 770 
lack of it, at nuclear domains that contain infecting HSV-1 genomes in transgenic PML depleted 771 
(shPML) or not (shCtrl) HFt cells within a developing plaque.  Cells were infected with 2 PFU of 772 
ICP0-null mutant HSV-1 (ΔICP0) per cell for 16 h.  PIAS1 (red), PML (cyan), and Daxx (cyan) 773 
were detected by indirect immunofluorescence.  (B) Confocal microscopy images show the 774 
nuclear localization of eYFP or eYFP-PIAS1 mutant proteins in HSV-1 infected cells within a 775 
developing plaque.  EYFP or eYFP-PIAS1 mutant protein expression was DOX induced for 4 h 776 
prior to infection with 2 PFU of ICP0-null mutant HSV-1 (ΔICP0) or 0.002 PFU of wild-type 777 
HSV-1 (HSV-1) per cell for 16 h.  ICP4 (red) and PML (cyan) were detected by indirect 778 
immunofluorescence.  The nuclear edge associated with HSV-1 genome entry is identified by 779 
ICP4 localization.  Nuclei were stained with DAPI (blue).  (C) Western blots show the 780 
expression level of eYFP-PIAS1 mutant proteins.  Protein expression was DOX induced for 0, 8, 781 
or 24 h prior to the collection of whole cell lysates.  Membranes were probed for PIAS1 and 782 
actin as a loading control.  MWs are indicated (kDa). 783 
 784 
FIG 6.  PIAS1 is not essential for PML-NB formation or PML SUMOylation, but does enhance 785 
the accumulation of SUMO1 in domains that contain infecting HSV-1 genomes.  (A) Western 786 
blots show PIAS1 protein levels in transgenic HFt cells that express PIAS1 specific (shPIAS1) or 787 
non-targeted control (shCtrl) shRNA.  Whole cell lysates were resolved by Tris-glycine SDS-788 
PAGE.  Membranes were probed for PIAS1 or PML, and actin as a loading control.  MWs are 789 
indicated (kDa).  (B) Confocal microscopy images show the localization of PML in transgenic 790 
shPIAS1 or shCtrl expressing cells.  PML (green) and PIAS1 (red) were detected by indirect 791 
immunofluorescence.  (C) Confocal microscopy images show the localization of Daxx, SUMO1, 792 
or SUMO2/3 in mock infected HFt cells that express shPIAS1 or shCtrl.  Daxx (green), PIAS1 793 
(red), SUMO1 (cyan), and SUMO2/3 (cyan) were detected by indirect immunofluorescence.  (D) 794 
Confocal microscopy images show the nuclear localization of PML, Daxx, SUMO1, or 795 
SUMO2/3 during ICP0-null mutant HSV-1 infection of transgenic HFt cells that express 796 
shPIAS1 or shCtrl.  Cells were infected with 2 PFU of ICP0-null mutant HSV-1 per cell for 16 h.  797 
PIAS1 (red), PML (cyan), Daxx (cyan), SUMO1 (cyan), and SUMO2/3 (cyan) were detected by 798 
indirect immunofluorescence.  The nuclear edge associated with HSV-1 genome entry was 799 
identified by eYFP.ICP4 localization.  Nuclei were stained with DAPI (blue). 800 
 801 
FIG 7.  PIAS1 repression of ICP0-null mutant HSV-1 replication is additive to that of PML.  (A) 802 
Bar graph shows the average relative levels of PML or PIAS1 mRNA in transgenic HFt cells that 803 
express shRNA against PML (shPML), PIAS1 (shPIAS1), or a non-targeted control (shCtrl).  804 
PML or PIAS1 mRNA levels were determined using the TaqMan system of quantitative RT-805 
PCR.  Values normalized to GAPDH expression using the ΔΔCt method are expressed relative to 806 
mock-infected cells (1.0).  Means and Standard Deviations (SD) are shown (n > 3).  (B) Western 807 
blots show PML or PIAS1 protein levels in transgenic HFt cells that express shPML, shPIAS1, 808 
or shCtrl.  Whole cell lysates were resolved by Tris-glycine SDS-PAGE.  Membranes were 809 
probed for PML or PIAS1, and actin as a loading control.  MWs are indicated (kDa).  (C) Bar 810 
graph shows the average relative plaque forming efficiency (PFE) of wild-type (HSV-1) or 811 
ICP0-null mutant (ΔICP0) HSV-1 in transgenic HFt cells that express shCtrl, shPML, or 812 
shPIAS1.  The number of plaques for each strain is expressed relative to the corresponding 813 
number of plaques for that strain in shCtrl expressing cells. Means and SD are shown (n = 6). 814 
Neo, neomycin; Puro, puromycin. 815 
 816 
FIG 8.  PIAS1 and PIAS4 cooperatively restrict ICP0-null mutant HSV-1 replication.  (A-B) 817 
Confocal microscopy images show the localization of PIAS1 and PIAS4 in HSV-1 infected cells.  818 
HFt cells were infected with 2 or 0.002 PFU per cell of ICP0-null mutant (A) or wild type HSV-819 
1 (B), respectively, for 16 h.  PIAS1 (red), PIAS4 (red), and PML (cyan) were visualized by 820 
indirect immunofluorescence.  Replication compartments were identified by the accumulation of 821 
eYFP.ICP4.  Insert (dashed box in (A)) highlights a region where PIAS1 and PML colocalize 822 
within a replication compartment.  Nuclei were stained with DAPI (blue).  (C) Western blots 823 
show PIAS1 or PIAS4 protein levels in transgenic HFt cells that express shRNA against PIAS1 824 
(shPIAS1), PIAS4 (shPIAS4), or a non-targeted control (shCtrl).  Whole cell lysates were 825 
resolved by Tris-glycine SDS-PAGE.  Membranes were probed for PIAS1 or PIAS4, and actin 826 
as a loading control.  MWs are indicated (kDa).  Puro, puromycin.  (D) Bar graph shows the 827 
average relative PFE of wild-type or ICP0-null mutant HSV-1 in transgenic HFt cells that 828 
express shPIAS1, shPIAS4, or shCtrl.  The number of plaques for each strain is expressed 829 
relative to the corresponding number of plaques for that strain in cells that express shCtrl.  830 
Means and SD are shown (n = 6).  831 
TABLE 1:  Primers for PIAS1 PCR mutagenesis and their corresponding substitution mutations. 832 
 833 
PIAS1  
Mutant 
PCR Primers for Mutagenesis Amino Acid 
Change Forward Reverse 
C351A 5'GGGCCCTTACAGCGTCTCATCTAC 5'GTAGATGAGACGCTGTAAGGGCCC C to A 
mSIM 5'GAAAGTAGAAGCGGCTGACCTAACCATAG 5'CTATGGTTAGGTCAGCCGCTTCTACTTTC VIDLT to AADLT 








